Zydus Lifesciences gets USFDA nod to market generic drug
Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to market a generic product which is used to treat myxedema coma.
The company has received the final approval for Levothyroxine Sodium for Injection in strength of 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the US Food and Drug Administration (USFDA), the drug firm said in a statement.
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma.
Zydus said the drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara (India).
Shares of the company were trading 0.19 per cent up at Rs 483.20 apiece on the BSE.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)